ABEONA THERAPEUTICS INC. (ABEO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 3.5M 7M 10.5M FY14: 925K FY15: 1M FY16: 889K FY17: 837K FY18: 3M FY20: 10M FY21: 3M FY22: 1.4M FY23: 3.5M FY25: 5.8M FY14 FY15 FY16 FY17 FY18 FY20 FY21 FY22 FY23 FY25

Gross Profit Annual

0 1.5M 3M 4.5M FY25: 4.3M FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-105M -70M -35M 0 35M 70M 105M FY16: -23.9M FY17: -27.8M FY18: -58.2M FY19: -77.1M FY20: -81.4M FY21: -89.8M FY22: -50.9M FY23: -47.1M FY24: -64.2M FY25: -89.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY16: -21.9M FY17: -27.3M FY18: -56.7M FY19: -76.3M FY20: -84.2M FY21: -84.9M FY22: -39.7M FY23: -54.2M FY24: -63.7M FY25: 71.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 600K 1.2M 1.8M FY25: 1.5M FY25

Operating Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M FY16: -13M FY17: -22.7M FY18: -39.1M FY19: -62.8M FY20: -35M FY21: -65.7M FY22: -43.5M FY23: -37M FY24: -56M FY25: -76.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M FY16: -13.5M FY17: -23.5M FY18: -48.4M FY19: -69.1M FY20: -36.4M FY21: -69.8M FY22: -43.6M FY23: -37.3M FY24: -58.5M FY25: -84.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY12: 24.2M FY13: 509.5K FY14: 1.9M FY15: 27.6M FY16: 34.2M FY21: 3.9M FY22: 7.9M FY23: 21.4M FY24: 41M FY25: 66.1M FY12 FY13 FY14 FY15 FY16 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '13: -0.17 Q2 '13: 0.32 Q4 '15: -0.51 Q1 '16: -0.58 Q2 '16: -0.62 Q3 '16: -0.51 Q4 '16: -0.64 Q1 '17: -0.60 Q2 '17: -0.61 Q3 '17: -0.66 Q4 '17: -0.66 Q1 '18: -0.75 Q2 '18: -0.80 Q3 '18: -1.01 Q4 '18: -1.18 Q1 '19: -1.35 Q2 '19: -1.58 Q3 '19: -1.59 Q4 '19: -1.53 Q1 '20: -1.66 Q2 '20: -1.31 Q3 '20: -1.04 Q4 '20: -0.91 Q1 '21: -0.56 Q3 '22: -3.90 Q4 '22: -5.53 Q1 '23: -2.27 Q2 '23: -4.55 Q3 '23: -4.03 Q4 '23: -2.58 Q1 '24: -3.20 Q2 '24: -2.54 Q3 '24: -2.69 Q4 '24: -2.19 Q1 '25: -1.27 Q2 '25: 0.70 Q3 '25: 1.23 Q4 '25: 1.01 Q1 '26: 0.95 Q2 '26: -1.11 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.